Growth hormone secretagogue
A compound that stimulates the pituitary gland to release growth hormone by activating the ghrelin receptor or GHRH receptor. Includes peptides (ipamorelin, GHRP-2, GHRP-6) and the oral compound MK-677.
Frequently Asked Questions
What is Growth hormone secretagogue?
Why is Growth hormone secretagogue important in peptide research?
Related Terms
Growth hormone-releasing hormone, a 44-amino acid hypothalamic peptide that stimulates pulsatile GH secretion from the anterior pituitary. Sermorelin, CJC-1295, and tesamorelin are synthetic analogs of GHRH.
IGF-1Insulin-like growth factor 1, a hormone produced primarily by the liver in response to growth hormone. Mediates many of GH’s anabolic effects including muscle growth, bone density, and tissue repair.
Receptor agonistA molecule that binds to and activates a receptor, triggering a biological response. Semaglutide is a GLP-1 receptor agonist; ipamorelin is a ghrelin receptor agonist.
Pulsatile dosingA dosing strategy that mimics the body’s natural pulsatile hormone release patterns. Used with growth hormone secretagogues to prevent receptor desensitization and maintain physiological GH release.
Related Peptide Profiles
A selective growth hormone secretagogue that stimulates GH release through the ghrelin receptor with minimal effect on cortisol or prolactin.
MK-677Ibutamoren, an oral growth hormone secretagogue that mimics ghrelin signaling to increase GH and IGF-1 levels over 24 hours.
CJC-1295A synthetic growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile GH secretion. Available with or without DAC (Drug Affinity Complex).